Bellicum Pharmaceuticals, Inc.
(NASDAQ : BLCM)

( )
BLCM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.13%154.400.0%$1242.28m
AMGNAmgen, Inc. 0.00%249.951.3%$706.86m
SNSSSunesis Pharmaceuticals, Inc. 0.00%8.000.7%$559.23m
NVAXNovavax, Inc. 0.18%195.0080.0%$540.62m
ILMNIllumina, Inc. 0.00%403.153.5%$527.32m
GILDGilead Sciences, Inc. -0.37%64.651.0%$470.67m
REGNRegeneron Pharmaceuticals, Inc. 0.51%479.472.7%$433.31m
VRTXVertex Pharmaceuticals, Inc. 0.07%216.101.9%$372.34m
ALXNAlexion Pharmaceuticals, Inc. 0.00%153.732.0%$315.33m
BIIBBiogen, Inc. 0.00%266.191.7%$292.97m
BNTXBioNTech SE 0.50%130.290.0%$219.90m
EXASEXACT Sciences Corp. 1.52%129.9518.4%$197.83m
NBIXNeurocrine Biosciences, Inc. 3.26%96.004.9%$178.12m
CRSPCRISPR Therapeutics AG 1.13%122.250.6%$171.27m
TXG10X Genomics, Inc. 0.00%197.360.0%$149.02m

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.